Genomics and Bioinformatics of Parkinson's Disease

  1. Howard J. Federoff1,4
  1. 1Department of Neuroscience, Georgetown University, Washington, DC 20057
  2. 2Department of Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057
  3. 3Department of Biochemistry, Molecular and Cellular Biology, Georgetown University, Washington, DC 20057
  4. 4Department of Neurology, Georgetown University, Washington, DC 20057
  1. Correspondence: hjf8{at}georgetown.edu

Abstract

Within the last two decades, genomics and bioinformatics have profoundly impacted our understanding of the molecular mechanisms of Parkinson's disease (PD). From the description of the first PD gene in 1997 until today, we have witnessed the emergence of new technologies that have revolutionized our concepts to identify genetic mechanisms implicated in human health and disease. Driven by the publication of the human genome sequence and followed by the description of detailed maps for common genetic variability, novel applications to rapidly scrutinize the entire genome in a systematic, cost-effective manner have become a reality. As a consequence, about 30 genetic loci have been unequivocally linked to the pathogenesis of PD highlighting essential molecular pathways underlying this common disorder. Herein we discuss how neurogenomics and bioinformatics are applied to dissect the nature of this complex disease with the overall aim of developing rational therapeutic interventions.

Also in this Collection

    | Table of Contents

    Richard Sever interviews Joan Brugge